Floatz logo

Als-L1023

Abdominal Obesity Metabolic Syndrome

Hanmi Pharmaceutical Company LimitedPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Abdominal Obesity Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Intralipid
University Health Network, Toronto
Phase 4BB
N-Acetyl-L-Cysteine
University Health Network, Toronto
Phase 4BB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
University of Sao Paulo
Phase 4BB
Eplerenone
Maastricht University Medical Center
Phase 4B
MK-0767
Merck Sharp & Dohme LLC
Phase 2CCC

Same molecule, other indications

Als-L1023 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →
age-related macular degenerationDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →